Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — ShareCafe Micro/Small Cap "Hidden Gems" Webinar (February 2021)
13 slides from Genetic Signatures's conference presentation, Feb 12, 2021
Slide 1: Investor Webinar Presentation
ASX Announcement 12 February 2021 Investor Webinar Presentation For personal use only Genetic Signatures Limited (ASX: GSS) (“Genetic Signatures” or “the Company”) is pleased to announce its participation in the Share Cafe Webinar - Micro/Small Cap "Hidden Gems" Webinar to be held today (Friday 12 F
Slide 2: ShareCafe Presentation February 2021
For personal use only ShareCafe Presentation February 2021
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This
Slide 4: Introducing Genetic Signatures
Introducing Genetic Signatures For personal use only Genetic Signatures Limited (ASX: GSS) Range of EasyScreen™ Kits Specialist molecular diagnostics company Enteric Detects 20+ gastroenteritis pathogens including Salmonella, Giardia and Norovirus) Focused on becoming a global leader in Respiratory
Slide 5: Trusted and Proven Technology
Trusted and Proven Technology For personal use only Our Products Transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays. Our automated sample preparation method is suitable for bacterial, protozoan and viral (DNA & RNA
Slide 6: Months in Review
12 Months in Review March 2020: For personal use only First shipments and regulatory submission for COVID-19 kit April 2020: CE-IVD received for SARS-CoV-2 kit April 2020: TGA registration of SARS-CoV-2 kit June 2020: Included in S&P/ASX All Ordinaries index June 2020: Record quarterly revenue up 35
Slide 7: Continued Strong Revenue Growth
Continued Strong Revenue Growth Increasing contribution from international business For personal use only Revenue (unaudited) from operations (A$m) • +744% on qtrly pcp and +646% vs 18.7 1H FY20 International APAC 3.6 • Strong demand for tests in 1H FY21 following second wave of COVID-19 in Australi
Slide 8: Asia Pacific Update
Asia Pacific Update For personal use only 1H21 revenue increased 619% to $15.1m (1H20: $2.5m) and includes instrument sales of $0.2m Received TGA registration and launched EasyScreen™ SARS-CoV-2 Detection Kit across Australia – Mar 20 Underpinned by strong demand for EasyScreen™ SARS-CoV-2 Det
Slide 9: EMEA Update
EMEA Update For personal use only European Union and UK are a key focus through FY21 and beyond Achieved European registration (CE-IVD) for the EasyScreen™ SARS-CoV-2 Detection Kit – Jan 21 1H21 revenue 3.0m, (1H20: $0.1m), including instrument sales of $0.6m, representing 16% of global 1H FY2
Slide 10: North America Update
North America Update For personal use only Largest market opportunity globally, representing an estimated 42% of the global molecular testing market1 First customers in USA, including Boston Medical Center – 1st orders supplied in December 2020 1H FY21 revenue $0.6m – 1st notable sales in USA
Slide 11: Multiple EasyScreen Kits Targeting Significant Addressable Markets
Multiple EasyScreenTM Kits Targeting Significant Addressable Markets For personal use only Commercial products available… Enteric Respiratory ESBL & CPO STI / Genital TGA / CE-IVD TGA / CE-IVD TGA / CE-IVD CE-IVD Submitted TGA ~$537m p.a1 ~$627m1 / $6.3bn Emerging market SARS-CoV-2 p.a2 ~A$1.9bn p.a
Slide 12: Looking Forward
Looking Forward Multiple growth opportunities to be pursued in tandem, creating significant upside potential For personal use only • Focus on securing long-term customer contracts with high throughput pathology Focus on long-term groups, hospitals or government run programs customer contracts • Prov
Slide 13: Contact us
For personal use only Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media
Genetic Signatures — ShareCafe Micro/Small Cap "Hidden Gems" Webinar (February 2021) on 6ix